MedPath

BIOHAVEN THERAPEUTICS LTD

πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

18

Active:3
Completed:3

Trial Phases

3 Phases

Phase 1:5
Phase 2:8
Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (17 trials with phase data)β€’ Click on a phase to view related trials

Phase 2
8 (47.1%)
Phase 1
5 (29.4%)
phase_2_3
3 (17.6%)
Not Applicable
1 (5.9%)

Study of BHV-1400 in IgA Nephropathy

Not Applicable
Recruiting
Conditions
IgA Nephropathy
Interventions
First Posted Date
2025-07-08
Last Posted Date
2025-10-15
Lead Sponsor
Biohaven Therapeutics Ltd.
Target Recruit Count
10
Registration Number
NCT07054684
Locations
πŸ‡ΊπŸ‡Έ

Site-009, Hinsdale, Illinois, United States

πŸ‡ΊπŸ‡Έ

Site-003, Miami Lakes, Florida, United States

πŸ‡ΊπŸ‡Έ

Site-005, Pembroke Pines, Florida, United States

and more 3 locations

Study of BHV-1300 in Graves' Disease

Phase 1
Recruiting
Conditions
Graves Disease
Interventions
First Posted Date
2025-05-20
Last Posted Date
2025-09-24
Lead Sponsor
Biohaven Therapeutics Ltd.
Target Recruit Count
15
Registration Number
NCT06980649
Locations
πŸ‡ΊπŸ‡Έ

Site-106, Houston, Texas, United States

πŸ‡¦πŸ‡Ί

Site-004, Fitzroy, Australia

πŸ‡¦πŸ‡Ί

Site-008, Parkville, Australia

and more 9 locations

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

Phase 2
Recruiting
Conditions
Parkinson Disease
Interventions
Drug: Placebo
First Posted Date
2025-05-16
Last Posted Date
2025-10-15
Lead Sponsor
Biohaven Therapeutics Ltd.
Target Recruit Count
550
Registration Number
NCT06976268
Locations
πŸ‡ΊπŸ‡Έ

Site-049, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

Site-024, Scottsdale, Arizona, United States

πŸ‡ΊπŸ‡Έ

Site-079, Sun City, Arizona, United States

and more 62 locations

A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Solid Tumor
Interventions
First Posted Date
2025-03-13
Last Posted Date
2025-09-16
Lead Sponsor
Biohaven Therapeutics Ltd.
Target Recruit Count
95
Registration Number
NCT06874335
Locations
πŸ‡ΊπŸ‡Έ

Site-106, West Valley City, Utah, United States

πŸ‡ΊπŸ‡Έ

Site-102, Fairfax, Virginia, United States

πŸ‡ΊπŸ‡Έ

Site-107, Denver, Colorado, United States

and more 9 locations

Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine

Phase 2
Completed
Conditions
Migraine
Interventions
Drug: Placebo
First Posted Date
2024-09-19
Last Posted Date
2025-07-08
Lead Sponsor
Biohaven Therapeutics Ltd.
Target Recruit Count
647
Registration Number
NCT06603623
Locations
πŸ‡ΊπŸ‡Έ

MD First Research, Gilbert, Arizona, United States

πŸ‡ΊπŸ‡Έ

WR-PRI, LLC (Encino), Encino, California, United States

πŸ‡ΊπŸ‡Έ

Cenexel CNS Los Alamitos, Los Alamitos, California, United States

and more 56 locations
  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.